Treatment administered to patients with acute promyelocytic leukemia
| Treatment . | Number of courses . | |
|---|---|---|
| Newly diagnosed . | Relapsed . | |
| Induction therapy | 63 | 28 |
| All-trans RA | 61 | 23 |
| 9-cisRA | 1 | 1 |
| All-trans RA + chemotherapy | 1 | 0 |
| Chemotherapy | 0 | 3 |
| BMT | 0 | 1 |
| Postremission therapy | 54 | 25 |
| Chemotherapy | 54 | 0 |
| 1 cycle | 1 | |
| 2 cycles | 3 | |
| 3 cycles | 42 | |
| 3 cycles + HuM195 | 6 | |
| 5 cycles | 1 | |
| 6 cycles | 1 | |
| All-trans RA maintenance | 0 | 11 |
| 131I-M195 | 0 | 7 |
| BMT | 0 | 4 |
| AuBMT | 0 | 2 |
| HuM195 maintenance | 0 | 1 |
| Treatment . | Number of courses . | |
|---|---|---|
| Newly diagnosed . | Relapsed . | |
| Induction therapy | 63 | 28 |
| All-trans RA | 61 | 23 |
| 9-cisRA | 1 | 1 |
| All-trans RA + chemotherapy | 1 | 0 |
| Chemotherapy | 0 | 3 |
| BMT | 0 | 1 |
| Postremission therapy | 54 | 25 |
| Chemotherapy | 54 | 0 |
| 1 cycle | 1 | |
| 2 cycles | 3 | |
| 3 cycles | 42 | |
| 3 cycles + HuM195 | 6 | |
| 5 cycles | 1 | |
| 6 cycles | 1 | |
| All-trans RA maintenance | 0 | 11 |
| 131I-M195 | 0 | 7 |
| BMT | 0 | 4 |
| AuBMT | 0 | 2 |
| HuM195 maintenance | 0 | 1 |
BMT indicates bone marrow transplantation; AuBMT, autologous bone marrow transplantation; 131I-M195, iodine-131–labeled M195 (anti-CD33 monoclonal antibody); HuM195, recombinant humanized M195.